Related Experiment Videos
Lactulose as an antiendotoxin in experimental colitis
K R Gardiner1, P J Erwin, N H Anderson
1Department of Surgery, Queen's University of Belfast, UK.
The British Journal of Surgery
|April 1, 1995
Summary
Lactulose effectively reduced endotoxin levels in a rat colitis model, while colistin decreased harmful bacteria. Both treatments show potential for managing inflammatory bowel disease complications.
Area of Science:
- Gastroenterology
- Microbiology
- Pharmacology
Background:
- Inflammatory bowel disease (IBD) is associated with systemic endotoxemia and altered gut microbiota.
- Current treatments for IBD may not fully address these complications.
Purpose of the Study:
- To evaluate lactulose's efficacy as an antiendotoxin agent.
- To investigate the impact of lactulose and colistin on fecal flora in a rat model of colitis.
Main Methods:
- A hapten-induced rat model of colitis was utilized.
- Enteral administration of lactulose or colistin was compared to water treatment.
- Systemic endotoxin levels and fecal bacterial counts were measured.
Main Results:
- Lactulose significantly reduced systemic endotoxin concentrations in colitic rats.
- Colistin administration markedly decreased fecal aerobic Gram-negative bacilli counts.
- Neither lactulose nor colistin significantly altered fecal endotoxin load.
Conclusions:
- Enteral lactulose may prevent systemic endotoxemia in patients with IBD.
- Enteral colistin could be beneficial for modifying enteric bacteria in IBD patients.
- Combined or individual use of these agents warrants further investigation for IBD management.